SCUELJapan healthcare data

Home › Japan pharmaceutical market › TNF inhibitors

Japan market size · Drug class

TNF inhibitors in Japan

TNFα阻害薬

The prescription value of TNF inhibitors (14 molecules) in Japan was an estimated ¥176 billion in FY2024. Value changed -8.5% year on year and -6.0% a year on average over the last three years. The largest molecule is Adalimumab (Genetical Recombination) (28%).

¥176bnValue FY2024 (single agents)
-8.5%Year on year
-6.0%3-year average growth

Trend and molecules

Hover or tap a year for the values.

Trend (single agents)

Prescription value (est.)YoY upYoY down

By molecule (FY2021 = 100)

Molecules in this class

Adalimumab (Genetical Recombination)アダリムマブ（遺伝子組換え）Golimumab (Genetical Recombination)ゴリムマブ（遺伝子組換え）Infliximab (Genetical Recombination)インフリキシマブ（遺伝子組換え）Etanercept (Genetical Recombination)エタネルセプト（遺伝子組換え）Certolizumab Pegol (Genetical Recombination)セルトリズマブ　ペゴル（遺伝子組換え）Etanercept (Genetical Recombination) [Etanercept Biosimilar 1]エタネルセプト（遺伝子組換え）［エタネルセプト後続１］Infliximab (Genetical Recombination) [Infliximab Biosimilar 1]インフリキシマブ（遺伝子組換え）［インフリキシマブ後続１］Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 4]アダリムマブ（遺伝子組換え）［アダリムマブ後続４］Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]アダリムマブ（遺伝子組換え）［アダリムマブ後続１］Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 3]アダリムマブ（遺伝子組換え）［アダリムマブ後続３］Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 2]アダリムマブ（遺伝子組換え）［アダリムマブ後続２］Etanercept (Genetical Recombination) [Etanercept Biosimilar 2]エタネルセプト（遺伝子組換え）［エタネルセプト後続２］Infliximab (Genetical Recombination) [Infliximab Biosimilar 3]インフリキシマブ（遺伝子組換え）［インフリキシマブ後続３］Infliximab (Genetical Recombination) [Infliximab Biosimilar 2]インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］
All markets

Need the numbers behind the lines?

Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.

Contact us

About the data

Values are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.